Aptar Pharma dose indicator selected for new asthma combination therapy – Packaging World


Packaging World

Aptar Pharma dose indicator selected for new asthma combination therapy
Packaging World
It is indicated for the maintenance treatment of asthma in patients aged 12 years and over, and in adults whose symptoms are not adequately controlled on an ICS and an as-required inhaled short-acting beta2-agonist (SABA), and in those patients who are

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.